Kromek Group PLC (LON:KMK) has further strengthened its relationship with the Defense Advanced Research Projects Agency (DARPA), part of the US Department of Defense, with a 12-month contract for biological threat detection systems carrying a value of US$1.99mln.
The contract, which began on 10 December, is to develop a proof-of-concept device for a vehicle-mounted biological-threat identifier but has potential to be extended to a multi-year project to develop a fully deployable system.
‘Dirty Bomb’ detectors
The bio-threat detection deal is the latest win in a relationship with DARPA that the company has cultivated throughout the year.
In March, Kromek was awarded an extension to a high-volume production contract with DARPA, worth around US$1.6mln, to enhance its D3S equipment that is already deployed at the agency.
D3S is part of the radiation detection range of Kromek’s products and was previously used at a NATO summit in July as part of the meeting’s security arrangements.
Inroads at DTRA
Aside from DARPA, the company also clinched a funding deal in September with DTRA, the Defense Threat Reduction Agency, also a part of the DoD.
The US$1.8mln in funding formed part of a previous agreement with DTRA in which Kromek will develop a next-generation radionuclide identification device for detecting radioactive substances.
The process involves the use of Kromek’s D3S platform to develop a next-generation, ruggedised small form factor for use in the military field.
Baggage scanning success
The firm is also seeing progress with its CZT range of detector modules, which it agreed to customise for baggage screening systems in a five-year, US$7.8mln deal in November.
CZT stands for cadmium zinc telluride, a semiconductor used for x-ray and gamma radiation detection that can operate at room temperature. The deal itself is with an existing client, an x-ray systems maker.
Medical contract wins
The firm’s CZT tech has also been picked up in the medical sector, receiving two orders in August that had a combined value of around US$1mln.
The orders included one from an equipment manufacturing customer has placed a US$700,000 order for Kromek’s CZT detectors to be used in nuclear medicine.
The other was a repeat contract in the bone mineral densitometry market for CZT detectors worth US$340,000.
Cancer to TNT
Headquartered in County Durham, Kromek designs, develops, and produces x-ray and gamma-ray imaging and radiation detection products for the medical, security screening, homeland security and civil nuclear markets.
Its products provide high-resolution information on material composition and structure.
Practically, the technology can be used to identify anything from cancerous tissue through to hazardous materials such as explosives and radioactive matter.
Kromek provides customers with radiation detector materials used for devices as well as finished products such as detectors.
As well as operations in the UK, it has bases in California and Pennsylvania in the US.
It sells directly to equipment manufacturers and via distributors.
Monday’s was one of a number of new contracts wins for the business, which included two new deals with the US government to supply radiation detection equipment.
With shares trading at around 26p, the company carries a market cap of £66.4mln.